Literature DB >> 19741614

PARP inhibitors blaze a trail in difficult-to-treat cancers.

Jim Kling.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19741614     DOI： 10.1038/nbt0909-784

Source DB:  PubMed          Journal:  Nat Biotechnol        ISSN： 1087-0156            Impact factor:   54.908


× No keyword cloud information.
  4 in total

1.  Genentech raises stakes on PARP inhibitors.

Authors:  Cormac Sheridan
Journal:  Nat Biotechnol       Date:  2006-10-05       Impact factor: 54.908

2.  High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs.

Authors:  Sven Rottenberg; Janneke E Jaspers; Ariena Kersbergen; Eline van der Burg; Anders O H Nygren; Serge A L Zander; Patrick W B Derksen; Michiel de Bruin; John Zevenhoven; Alan Lau; Robert Boulter; Aaron Cranston; Mark J O'Connor; Niall M B Martin; Piet Borst; Jos Jonkers
Journal:  Proc Natl Acad Sci U S A       Date:  2008-10-29       Impact factor: 11.205

3.  Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase.

Authors:  Helen E Bryant; Niklas Schultz; Huw D Thomas; Kayan M Parker; Dan Flower; Elena Lopez; Suzanne Kyle; Mark Meuth; Nicola J Curtin; Thomas Helleday
Journal:  Nature       Date:  2005-04-14       Impact factor: 69.504

4.  Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers.

Authors:  Peter C Fong; David S Boss; Timothy A Yap; Andrew Tutt; Peijun Wu; Marja Mergui-Roelvink; Peter Mortimer; Helen Swaisland; Alan Lau; Mark J O'Connor; Alan Ashworth; James Carmichael; Stan B Kaye; Jan H M Schellens; Johann S de Bono
Journal:  N Engl J Med       Date:  2009-06-24       Impact factor: 91.245
  4 in total
  9 in total

1.  PARP inhibitors stumble in breast cancer.

Authors:  Malini Guha
Journal:  Nat Biotechnol       Date:  2011-05       Impact factor: 54.908

2.  Selective small molecule inhibition of poly(ADP-ribose) glycohydrolase (PARG).

Authors:  Kristin E Finch; Claire E Knezevic; Amanda C Nottbohm; Kathryn C Partlow; Paul J Hergenrother
Journal:  ACS Chem Biol       Date:  2012-01-26       Impact factor: 5.100

3.  Ovarian cancer and DNA repair: DNA ligase IV as a potential key.

Authors:  Joana Assis; Deolinda Pereira; Rui Medeiros
Journal:  World J Clin Oncol       Date:  2013-02-10

4.  Loss of CtIP disturbs homologous recombination repair and sensitizes breast cancer cells to PARP inhibitors.

Authors:  Junhui Wang; Qianshan Ding; Hiroaki Fujimori; Akira Motegi; Yoshio Miki; Mitsuko Masutani
Journal:  Oncotarget       Date:  2016-02-16

5.  Hyper-active non-homologous end joining selects for synthetic lethality resistant and pathological Fanconi anemia hematopoietic stem and progenitor cells.

Authors:  Wei Du; Surya Amarachintha; Andrew F Wilson; Qishen Pang
Journal:  Sci Rep       Date:  2016-02-26       Impact factor: 4.379

6.  PARP inhibitors and the treatment of breast cancer: beyond BRCA1/2?

Authors:  Kristine M Frizzell; W Lee Kraus
Journal:  Breast Cancer Res       Date:  2009-11-26       Impact factor: 6.466

7.  Functional Aspects of PARP1 in DNA Repair and Transcription.

Authors:  Hui Ling Ko; Ee Chee Ren
Journal:  Biomolecules       Date:  2012-11-12

8.  Niraparib (MK-4827), a novel poly(ADP-Ribose) polymerase inhibitor, radiosensitizes human lung and breast cancer cells.

Authors:  Kathleen A Bridges; Carlo Toniatti; Carolyn A Buser; Huifeng Liu; Thomas A Buchholz; Raymond E Meyn
Journal:  Oncotarget       Date:  2014-07-15

9.  Ran Binding Protein 9 (RanBP9) is a novel mediator of cellular DNA damage response in lung cancer cells.

Authors:  Dario Palmieri; Mario Scarpa; Anna Tessari; Rexhep Uka; Foued Amari; Cindy Lee; Timothy Richmond; Claudia Foray; Tyler Sheetz; Ashley Braddom; Christin E Burd; Jeffrey D Parvin; Thomas Ludwig; Carlo M Croce; Vincenzo Coppola
Journal:  Oncotarget       Date:  2016-04-05
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.